Envolimab developer not widely established

Alphamab Oncology is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative biologics for oncology. The company is best known for developing Envafolimab (also known as Envolimab or KN035), the world's first subcutaneous PD-L1 inhibitor, which is approved in China for the treatment of MSI-H/dMMR advanced solid tumors. Alphamab utilizes its proprietary protein engineering platforms, such as CRIB (Charge Repulsion Improved Bispecific) and CRIB-sdAb, to create a diverse pipeline of bispecific antibodies and single-domain antibodies (nanobodies). Their lead bispecific candidates, KN046 and KN026, are in late-stage clinical trials for various indications including lung and gastric cancers. The company operates a fully integrated biologics platform with state-of-the-art GMP manufacturing facilities in Suzhou, China.